2023-05-04 18:04:38 ET
- Immuneering press release ( NASDAQ: IMRX ): Q1 GAAP EPS of -$0.51 beats by $0.04 .
- Cash and cash equivalents and marketable securities as of March 31, 2023 were $91.5 million, compared with $105.5 million as of December 31, 2022.
- Based on cash, cash equivalents and marketable securities, as of March 31, 2023, including estimated net proceeds from the April 2023 underwritten offering, and current operating plans, the company expects its cash runway to extend into 2025.
For further details see:
Immuneering GAAP EPS of -$0.51 beats by $0.04